Target Safety Assessment: Strategies and Resources, Chapter 12 of Drug Safety Evaluation Methods in Molecular Biology (vol 1641), was written by Dr Richard J Brennan, a Scientific Advisor at Sanofi in the United States. The chapter presents a summary of the information types and sources that should be investigated and approaches that can be [...]
ApconiX has a vacancy for a Research Scientist based at the BioHub, Alderley Park, UK ApconiX is an integrated toxicology and ion channel company that brings together a team of dedicated world-class experts to ensure that potential new medicines are safe for patients. We work with other companies, charities, academic institutions and government agencies across [...]
Sygnature Discovery recently hosted a lecture by Professor Ruth Roberts and Dr Michael Morton from ApconiX. Based at BioCity in Nottingham, Sygnature Discovery is the UK’s largest independent provider of integrated drug discovery resource and expertise. The theme of the lecture and subsequent debate with the attendees was 'Safety considerations in early chemical design: Challenges and [...]
Ruth Roberts is first author on one of Toxicological Sciences’ top 10% downloaded articles during the last 2 years. The paper, ‘Translational Biomarkers of Neurotoxicity: A Health and Environmental Sciences Institute Perspective on the Way Forward’ describes the challenges and opportunities in the development of biomarkers of neurotoxicity, a goal shared by scientists across academia, [...]
In February, APTrans signed a service agreement with Evgen Pharma to provide support to their lead program, SFX-01. Evgen Pharma is a clinical stage drug development company with projects in breast cancer and subarachnoid haemorrhage. APTrans is a consortium of companies based at the BioHub at Alderley Park, formed by ApconiX, Aptus Clinical and Seda [...]
ApconiX Associate Jane Stewart is first author on a manuscript in the DIA peer-reviewed journal “Therapeutic Innovation and Regulatory Science” (TIRS) that has received the DIA’s 2017 Author of the Year Award. This annual award honours the author of the most accessed and downloaded article in TIRS. The article ‘Birth Control in Clinical Trials: [...]
As we get ready for a busy and exciting 2017, it’s a good time to reflect on ApconiX’s first full year in business and share some notable highlights. In 2016 we were joined by several additional preclinical experts including Dr Guy Healing, Dr Damian Deavall, Dr Jane Barber, Dr Mike O’Donovan and Dr Peter Ballard [...]
ApconiX is going from strength to strength in delivering integrated toxicology expertise. But we realised we had a few key skills missing; to address this we have brought in 2 new experts, Jane Barber and Peter Ballard. As a senior toxicologist with expertise in cancer research, mechanistic problem and hepatotoxicity, Jane joins us to strengthen [...]
We had an exciting two days exhibiting at the European Laboratory Research & Innovation Group (ELRIG) Drug Discovery conference 2016 in Liverpool. Many new and old colleagues were interested to hear what services ApconiX offer and the successes we have had over the past year. It was a great team success creating the stall and [...]
We were delighted to welcome Tatton MP George Osborne on his visit to ApconiX earlier this month. Mr Osborne was shown around our state of the art laboratories by co-directors and partners Dr Michael Morton and Dr Richard Knight. Since ApconiX was founded in 2015, it has grown rapidly by providing world-class nonclinical safety expertise [...]
